A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2 study to evaluate the efficacy and safety of the anti-
programmed cell death-1(PD-1) monoclonal antibody F520 in participants with locally advanced
or metastatic Urothelial Cancer (UC).